Clinical Information

Clinical Indications

This assay measures IgA antibodies directed against cardiolipin and may provide supportive information in the evaluation of patients suspected of having:

• Antiphospholipid syndrome (APS), particularly when standard (“criteria”) antiphospholipid antibody tests are negative or inconclusive
• Systemic lupus erythematosus (SLE) or related autoimmune conditions
• Unexplained thrombotic events or selected pregnancy complications when clinical suspicion remains high

Testing may also be considered in selected patients being evaluated for autoimmune disorders associated with antiphospholipid antibodies.

Clinical Background

Antiphospholipid syndrome is an autoimmune condition characterized by thrombotic events and/or specific pregnancy complications in association with persistent antiphospholipid antibodies. Traditional laboratory criteria include lupus anticoagulant testing and IgG/IgM antibodies to cardiolipin and beta-2 glycoprotein I.

Antiphospholipid antibodies may also be detected in patients with systemic autoimmune diseases, particularly SLE. Additional clinical features sometimes associated with these antibodies include thrombocytopenia, livedo reticularis, cardiac valve abnormalities, renal involvement, and neurologic manifestations.

IgA isotypes of cardiolipin antibodies are not part of the traditional APS laboratory criteria. Nonetheless, measurement of IgA antibodies may be informative in selected cases, especially when clinical suspicion persists despite negative IgG and IgM testing. Current evidence suggests that isolated IgA positivity is uncommon and is typically seen in conjunction with other antiphospholipid antibody isotypes.

Detection of cardiolipin IgA is performed using solid-phase immunoassay methods. Because assay design and calibration vary among manufacturers, reported values are method-specific and should not be compared across platforms.

Reference Intervals

Results are reported in APL units (IgA phospholipid units).

• <15.0 APL: Negative
• 15.0–39.9 APL: Weakly positive
• 40.0–79.9 APL: Positive
• ≥80.0 APL: Strongly positive

Reference ranges apply to all age groups.

Result Interpretation

• Elevated cardiolipin IgA levels may be observed in patients with APS or SLE and should be interpreted in the context of clinical findings and additional laboratory studies.
• Because cardiolipin IgA is not included among formal APS laboratory criteria, isolated positivity requires cautious interpretation, particularly when other antiphospholipid antibodies are absent.
• Demonstration of antibody persistence on repeat testing strengthens clinical relevance and aligns with best practice principles used for criteria antiphospholipid antibodies.
• Anticoagulant therapy does not interfere with measurement of cardiolipin IgA using this assay.

Limitations and Important Considerations

• This assay is intended as an adjunctive tool and should not be used alone to diagnose or exclude APS, SLE, or other autoimmune conditions.
• Antiphospholipid antibodies may be transiently detected during acute infections or inflammatory states. Repeat testing may be appropriate to confirm persistence.
• Positive results can occur in other conditions, including infectious diseases and certain autoimmune or inflammatory disorders. Clinical correlation is essential.
• A proportion of patients with active syphilis may demonstrate cardiolipin antibody reactivity; confirmatory evaluation should be considered when clinically indicated.
• Results obtained using different commercial assays may not be directly comparable due to methodological variability.
• Treatment decisions should not be based solely on antibody detection in the absence of supportive clinical criteria.
• Immune complexes or nonspecific binding phenomena may contribute to false-positive reactivity in immunoassay-based methods.
• Assay validation has been established for serum specimens only.